Top Authors

• Most frequent coverage on CEGE

• 
  Alan Brochstein (703 followers)

  • Cancer Stocks: Tracking the Market (Mon, Jul 9)
  • Cancer Stocks: The Bleeding Slows (Mon, Jul 2)
  • Cancer Stocks Hammered Once Again (Tue, Jun 26)

  More by Alan Brochstein on CEGE »
• 
  Centient Biotech Investor (10 followers)

  • Biotech Day In Review: Genentech Beats Estimates Slightly (Thu, Apr 12)
  • Biotech Day In Review: Cell Genesys Climbs On GVAX Results (Wed, Apr 4)
  • Biotech Week In Review: Barron’s Touts Alzheimers Drugs From Wyeth (Mon, Apr 2)

  More by Centient Biotech Investor on CEGE »
• 
  Michael Shulman (247 followers)

  • Antigenics, Dendreon and Cell Genesys Find Hope in Overseas Treatment Approvals (Fri, Apr 11)
  • Which Has a Better Risk/Reward Ratio - Citigroup or Cell Genesys? (Fri, Apr 4)
  • Amgen: Boxed In (Mon, Jan 7)

  More by Michael Shulman on CEGE »

• Most followed authors on CEGE

• 
  VFC's Stock House (1131 followers)

  • La Jolla Is Too Much of a Gamble Right Now (Wed, Sep 2)
  • 4 Small Cap Stock Briefs (Wed, Jun 24)

  More by VFC's Stock House on CEGE »
• 
  Alan Brochstein (703 followers)

  • Cancer Stocks: Tracking the Market (Mon, Jul 9)
  • Cancer Stocks: The Bleeding Slows (Mon, Jul 2)
  • Cancer Stocks Hammered Once Again (Tue, Jun 26)

  More by Alan Brochstein on CEGE »
• 
  M. E. Garza (508 followers)

  • Transformative Times for BioSante Pharmaceuticals (Wed, Oct 21)

  More by M. E. Garza on CEGE »

• Newest authors on CEGE

• 
  M. E. Garza (508 followers)

  • Transformative Times for BioSante Pharmaceuticals (Wed, Oct 21)

  More by M. E. Garza on CEGE »
• 
  The Burrill Report (173 followers)

  • Dealmaking Sweeps the Biotech Sector (Sun, Jul 5)

  More by The Burrill Report on CEGE »
• 
  VFC's Stock House (1131 followers)

  • La Jolla Is Too Much of a Gamble Right Now (Wed, Sep 2)
  • 4 Small Cap Stock Briefs (Wed, Jun 24)

  More by VFC's Stock House on CEGE »

• Most commented on CEGE

• 
  Michael Shulman (247 followers)

  • Antigenics, Dendreon and Cell Genesys Find Hope in Overseas Treatment Approvals (Fri, Apr 11)
  • Which Has a Better Risk/Reward Ratio - Citigroup or Cell Genesys? (Fri, Apr 4)
  • Amgen: Boxed In (Mon, Jan 7)

  More by Michael Shulman on CEGE »
• 
  Alan Brochstein (703 followers)

  • Cancer Stocks: Tracking the Market (Mon, Jul 9)
  • Cancer Stocks: The Bleeding Slows (Mon, Jul 2)
  • Cancer Stocks Hammered Once Again (Tue, Jun 26)

  More by Alan Brochstein on CEGE »
• 
  Ohad Hammer (173 followers)

  • Cell Genesys’ GVAX: A Multi-Trick Pony (Mon, Jul 30)
  • Cell Genesys: The Promise of GVAX (Mon, May 7)

  More by Ohad Hammer on CEGE »